New York (ots/PRNewswire)
- Lipitor Reduces Risk of Major Cardiovascular Events Such as
Heart Attacks in People With Heart Disease and With a Cluster of
Other Major Cardiovascular Risk Factors, Often Referred to as
Metabolic Syndrome, New Analysis Shows
- Heart Disease Patients With Metabolic Syndrome who Took Lipitor 80mg
Dose Reduced Their Risk of Major Cardiovascular Events by Nearly 30
- Study Investigator: 'This is the largest analysis conducted in patients
on a statin with pre-existing heart disease and metabolic syndrome.
These data support the urgency of intensive LDL lowering to prevent
cardiovascular events in this very high risk patient population.'
A combination of risk factors that includes abdominal obesity, low
"good" cholesterol (HDL), high blood pressure and elevated blood
sugar occurs in nearly one in four Americans and places them at
increased risk for cardiovascular events, including heart attacks and
stroke. This combination of risk factors, which has been referred to
as metabolic syndrome, adds to the risk for cardiovascular events
already associated with high "bad" cholesterol (LDL).
New data published this week in the online version of The Lancet
show that in patients with pre-existing heart disease who also had a
specific cluster of cardiovascular risk factors, consistent with the
metabolic syndrome, intensive treatment with Lipitor 80mg reduced
their chances of having a heart attack or stroke. This is the largest
analysis conducted to assess heart disease patients who have
metabolic syndrome and have taken statins.
According to this secondary analysis, patients with heart disease
and metabolic syndrome who took the Lipitor 80mg dose reduced their
risk of major cardiovascular events such as heart attacks by nearly
30 percent compared with those who remained on the lower dose of
Lipitor 10mg. Both Lipitor 80mg and Lipitor 10mg were well-tolerated
in this patient population over the follow-up period of nearly 5
These findings are from an analysis of 5584 patients with heart
disease and who met National Cholesterol Education Program
(NCEP)-based criteria for metabolic syndrome from the Treating to New
Targets (TNT) trial of more than 10,000 patients. These findings are
consistent with the overall results of the TNT study, which
demonstrated the cardiovascular benefits of lowering cholesterol
levels to well below recommended levels with Lipitor 80mg in patients
with coronary heart disease, compared to lowering cholesterol to
within the minimum recommended levels with Lipitor 10mg.
"This is the largest analysis conducted in patients on a statin
with pre-existing heart disease and metabolic syndrome. These data
support the urgency of intensive LDL lowering to prevent
cardiovascular events in this very high-risk patient population,"
said Dr. Prakash C Deedwania, investigator for the Treating to New
Targets (TNT) study, Chief, Cardiology Division, Veterans
Administration Medical Center/UCSF program at Fresno, and Professor
of Medicine, UCSF School of Medicine, San Francisco.
This analysis also illustrated that in TNT, patients with
metabolic syndrome were more likely to experience a major
cardiovascular event than those without these risk factors. In
addition, the analysis showed that every additional cardiovascular
risk factor increased a patient's risk of experiencing a
cardiovascular event. Patients who had a higher number of risk
factors and received intensive treatment with Lipitor 80mg had fewer
cardiovascular events compared with patients taking the Lipitor 10mg
TNT was an investigator-led trial sponsored by Pfizer.
Important Information about Lipitor:
Lipitor is a prescription drug. It is used in patients with
multiple risk factors for heart disease, such as family history, high
blood pressure, age, low HDL ("good" cholesterol), or smoking to
reduce the risk of heart attack and stroke. When diet and exercise
alone are not enough, Lipitor is used along with a low-fat diet and
exercise to lower cholesterol.
Lipitor is also used in patients with type 2 diabetes and at least
one other risk factor for heart disease, such as high blood pressure,
smoking or complications of diabetes, including eye disease and
protein in urine, to reduce the risk of heart attack and stroke.
Lipitor is not for everyone. It is not for those with liver
problems. And it is not for women who are nursing, pregnant or may
become pregnant. If you take Lipitor, tell your doctor if you feel
any new muscle pain or weakness. This could be a sign of rare but
serious muscle side effects. Tell your doctor about all medications
you take. This may help avoid serious drug interactions. Your doctor
should do blood tests to check your liver function before and during
treatment and may adjust your dose. The most common side effects are
gas, constipation, stomach pain and heartburn. They tend to be mild
and often go away. For more product information visit
or call +1-888-LIPITOR.
Note to News Media:
- Study investigators will be available to discuss the TNT analysis in
- This analysis will be published in the online version of The Lancet on
Tuesday, September 5, 2006
Web site: http://www.pfizer.com
ots Originaltext: Pfizer Inc.
Im Internet recherchierbar: http://www.presseportal.ch
Lindley Green, Sept. 2-5: +1-917-543-3168, or after Sept. 5:
+1-212-798-9743; or Vanessa Aristide, cell, +1-917-697-0481, office,
+1-212-733-3784, both for Pfizer. Company News On-Call: Pfizer's
press releases are available through PR Newswire's Company News
On-Call service on PRN's Web Site. Visit
; Photo: A free corporate
logo to accompany this story is available immediately via Wieck Photo
Database to any media with telephoto receiver or electronic darkroom,
PC or Macintosh, that can accept overhead transmissions. To retrieve
a logo, please call +1-972-392-0888.